Johnson & Johnson (NYSE:JNJ) Trading 0.3% Higher – Should You Buy?

Johnson & Johnson (NYSE:JNJ)’s stock price shot up 0.3% on Friday . The company traded as high as $147.63 and last traded at $147.10. 1,935,969 shares changed hands during trading, a decline of 78% from the average session volume of 8,953,900 shares. The stock had previously closed at $146.64.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Barclays decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 21st. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Bank of America dropped their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.06.

Johnson & Johnson Stock Up 0.1 %

The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market cap of $353.34 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. The firm’s 50 day simple moving average is $147.85 and its two-hundred day simple moving average is $155.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.29 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Tempus Wealth Planning LLC grew its holdings in shares of Johnson & Johnson by 6.2% during the 4th quarter. Tempus Wealth Planning LLC now owns 9,352 shares of the company’s stock valued at $1,353,000 after purchasing an additional 544 shares during the last quarter. Flavin Financial Services Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $672,000. Calamos Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 137.4% in the 4th quarter. Calamos Wealth Management LLC now owns 100,947 shares of the company’s stock valued at $14,599,000 after acquiring an additional 58,424 shares during the last quarter. Calamos Advisors LLC boosted its holdings in shares of Johnson & Johnson by 0.5% during the 4th quarter. Calamos Advisors LLC now owns 564,754 shares of the company’s stock valued at $81,675,000 after acquiring an additional 2,888 shares in the last quarter. Finally, Columbus Macro LLC increased its holdings in Johnson & Johnson by 59.0% in the 4th quarter. Columbus Macro LLC now owns 16,501 shares of the company’s stock worth $2,386,000 after purchasing an additional 6,120 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.